Recombinant anti-PD-L1/TGF-β bispecific antibody

重组抗PD-L1和TGF-β双特异性抗体

Report date: 2023/03/20 20:00:20

Base Information

Drug NameRecombinant anti-PD-L1/TGF-β bispecific antibody

Drug Alias NameY101DY-101D

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersAnti-TGF-β

TargetsProgrammed death-ligand 1Transforming growth factor beta

Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesWuhan Yzy Biopharma Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Yzy Biopharma Co Ltd

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsSolid tumoursCarcinoma, Hepatocellular

Other Information

ATC CodeN/A